News Tenaya Therapeutics, Inc.

Stocks

TNYA

US87990A1060

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 09:33:58 2026-07-16 am EDT			5-day change	1st Jan Change
0.8050 ^USD	-4.53%		-4.17%	+18.51%

Jun. 29	Tenaya Therapeutics, Inc. Announces Management Changes, Effective July 13, 2026	CI
Jun. 29	Tenaya Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective July 13, 2026	CI

All News

Mentions Relevance

Jul. 14	Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)	AQ
Jun. 29	Tenaya Therapeutics, Inc. Announces Management Changes, Effective July 13, 2026	CI
Jun. 29	Tenaya Therapeutics, Inc. Announces Chief Financial Officer Changes, Effective July 13, 2026	CI
Jun. 29	Tenaya Therapeutics Names Eric Hyllengren CFO	MT
Jun. 29	Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer	AQ
Jun. 05	Tenaya Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2026, Jun-04-2026 03:10 PM
Jun. 03	Tenaya Therapeutics, Inc. - Special Call
Jun. 03	Tenaya Therapeutics Announces Interim Data from MyPEAK™-1 Showing Treatment of MYBPC3-associated HCM with TN-201 Gene Therapy Resulted in Consistent Signs of Cardiac Remodeling and Reductions in Symptoms	AQ
Jun. 02	Tenaya Therapeutics to Announce New Interim Data from MyPEAK™-1 Phase 1b/2 Trial of TN-201 for Adults with MYBPC3-Associated HCM on Wednesday, June 3, 2026	AQ
Jun. 02	Tenaya Therapeutics, Inc. Announces New Interim Data From MyPEAK-1 Phase 1b/2 Trial Of TN-201 For Adults With MYBPC3-Associated HCM	CI
May. 29	Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026	AQ
May. 15	Tenaya Therapeutics, Inc. - Special Call
May. 15	Tenaya Therapeutics : Data from RIDGE-1 Phase 1b/2 Clinical Trial of TN-401 in Adults with PKP2-associated ARVC Presented at ASGCT 2026 Presentation (d2e3d8)	PU
May. 15	Positive interim data from cohorts 1 and 2 of Tenaya's Ridge-1 phase 1b/2 clinical trial of TN-401	RE
May. 15	Positive Interim Data from Cohorts 1 and 2 of Tenaya’s RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Demonstrated Consistent Reductions in Arrhythmia Burden for Adults with PKP2-associated ARVC	AQ
May. 15	Tenaya Therapeutics Presents Interim Data From Ridge-1 Phase 1b/2 Clinical Trial Of TN-401 Gene Therapy For PKP2-Associated ARVC	CI
May. 06	Tenaya Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 06	Tenaya Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
Apr. 27	Tenaya Therapeutics Announces Late-Breaking Oral Presentation of New Clinical Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy in Adults with PKP2-Associated ARVC at ASGCT 2026	AQ
Apr. 27	Tenaya Therapeutics Announces New Clinical Data and Pipeline Innovations	CI
Mar. 18	Tenaya Therapeutics, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 01:00 PM
Mar. 11	Tenaya Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Mar. 11	Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update	AQ
Mar. 09	Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy	AQ
Mar. 09	Tenaya Therapeutics Presents Preclinical Data Highlighting Tn-301?S Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy	CI